恩替卡韦联合院制协定3方治疗慢性乙肝早期肝硬化35例

目的探讨恩替卡韦联合院制协定3方中西医结合治疗慢性乙肝早期肝硬化的临床疗效。方法将70例慢性乙肝早期肝硬化患者随机分为观察组和对照组,各35例。对照组患者单用恩替卡韦治疗,观察组患者在对照组治疗基础上加用院制协定3方治疗。结果治疗后,观察组总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、白蛋白(ALB)、凝血酶原活动度(PTA)水平均得到显著改善,且改善程度显著优于对照组(P<0.05);观察组血清肝纤维化指标透明质酸酶(HA)、层黏蛋白(LN)、Ⅳ胶原(ⅣC)和Ⅲ型胶原(PCⅢ)均显效明显,与对照组比较差异有统计学意义(P<0.05)。结论恩替卡韦联合院制协定3方中西医结合治疗慢性乙肝早期肝硬化临床疗效显著,值得临床推广。

Objective To investigate the curative effect of Entecavir combined with the 3 agreement prescription Chinese and Western medicine in the treatment of chronic hepatitis B with early cirrhosis.Methods Totally 70 patients with chronic hepatitis B cirrhosis were randomly divided into observation group and control group,the control group was treated with Entecavir,on the basis of in the control group,the observation group was treated with the 3 agreement prescription in hospital.Results After treatment,TBIL,ALT,ALB and PTA in the observation group were significantly improved,and compared with the control group after treatment had significant difference(P<0.05),the serum liver fibrosis indexes HA,LN,IVC and PCⅢwere improved significantly,there was statistically significant difference compared with control group(P<0.05).Conclusion The combination of Enteavir combined with 3 agreement prescription of traditional Chinese medicine and Western medicine in the treatment of chronic hepatitis B with early liver cirrhosis is effective,which is worthy of clinical promotion.